The double marker test, conducted during the first trimester (typically between 9 and 13 weeks), is important for several reasons:
Screening for Chromosomal Abnormalities: It measures two specific substances in the mother's blood—human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein-A (PAPP-A). Abnormal levels can indicate an increased risk of conditions like Down syndrome and trisomy 18.
Risk Assessment: The test helps estimate the risk of chromosomal abnormalities, allowing for informed decision-making regarding further testing or monitoring.
Combination with Other Tests: The double marker test is often used alongside the nuchal translucency (NT) scan for a more comprehensive risk assessment.
Early Detection: Identifying potential issues early in the pregnancy can lead to better management options and planning for the future.
Non-Invasive: As a blood test, it poses no risk to the fetus, making it a safer option compared to invasive tests like amniocentesis.
Screening for Chromosomal Abnormalities: It measures two specific substances in the mother's blood—human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein-A (PAPP-A). Abnormal levels can indicate an increased risk of conditions like Down syndrome and trisomy 18.
Risk Assessment: The test helps estimate the risk of chromosomal abnormalities, allowing for informed decision-making regarding further testing or monitoring.
Combination with Other Tests: The double marker test is often used alongside the nuchal translucency (NT) scan for a more comprehensive risk assessment.
Early Detection: Identifying potential issues early in the pregnancy can lead to better management options and planning for the future.
Non-Invasive: As a blood test, it poses no risk to the fetus, making it a safer option compared to invasive tests like amniocentesis.
Keywords
